The randomized, double-blind, CONVOKE trial evaluated the safety and efficacy of CT-155, a PDT that provides interactive psychosocial intervention techniques via a smartphone app.

Event rates were lower during oseltamivir-treated influenza periods and posttreatment periods vs. untreated influenza ...

(HealthDay News) — US Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has canceled nearly $500 million in grants and contracts meant to support mRNA vaccine development, ...

Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

(HealthDay News) — A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have a ...

As part of a postmarketing requirement, Valneva will be initiating a study to assess the risk of severe chikungunya-like adverse reactions following administration of Ixchiq.

No significant increases seen in rate of hospital contacts for any of 29 adverse events in 28-day risk period after vaccination.

Kerendia (finerenone) Nonsteroidal mineralocorticoid receptor antagonist. To reduce the risk of cardiovascular death, hospitalization for heart failure (HF), and urgent HF visits in adult patients ...

Adults engaged in risky drinking should be provided brief behavioral counseling interventions to reduce use.

Stronger differential effect for CPAP seen for those without excessive sleepiness, without increased blood pressure.

HealthDay News — Canagliflozin is associated with a clinically meaningful reduction in hemoglobin A1c (HbA1c) for children and adolescents with type 2 diabetes mellitus (T2DM), according to a study ...

The FDA has approved Ajovy (fremanezumab) for the prevention of episodic migraine in pediatric patients aged 6 to 17 years weighing at least 45kg.